Ensysce Biosciences, Inc. (ENSC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on May 22, 2026, regarding an event that occurred on May 21, 2026. The Company is a Delaware corporation with its principal executive offices in La Jolla, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ENSC."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding stockholders' equity.
Material Changes and Events
On May 21, 2026, the Company received notice from Nasdaq stating it is non-compliant with Listing Rule 5550(b)(1) due to failing to meet the $2.5 million stockholders' equity requirement as of March 31, 2026. Consequently, the Company is subject to delisting unless it submits a plan to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company must submit a plan to regain compliance within 45 days (by July 6, 2026).
- Extension Possibility: If the plan is accepted, the Company may be granted an extension of up to 180 days from May 21, 2026, to achieve compliance.
- Appeal Process: If the plan is not accepted, the Company may appeal to the Nasdaq Hearings Panel.
- Risk Factors: Management states there can be no assurance that Nasdaq will accept the plan, that the Hearings Panel will accept an appeal, or that the Company will evidence compliance before any granted extension expires.
Key Facts for Investor Verification
- Verify the Company's stockholders' equity balance as of March 31, 2026, to confirm the deficiency below the $2.5 million threshold.
- Monitor the submission of the compliance plan by the July 6, 2026 deadline.
- Review the Company's proposed strategy for regaining compliance (e.g., capital raise, asset sale, or other measures).
- Check for any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq.